Studies in human breast cancer cell lines and animal models have reported that genistein inhibits DNMT1; reduces the promoter methylation of BRCA genes and other tumor suppressors, thus reactivating them and promoting their protective role; enhances chromatin acetylation marks; and modulates miRNAs (e.g., upregulates tumor-suppressive and proapoptotic miRNAs and downregulates the oncogenic ones) in diverse cancer types [172,173,174]. This evidence concerns the gene DNMT1 and neoplasm.